However, the administration of TPO-RAs in patients with severe ITP is still limited, partly due to its long response time; it usually takes 2–4 weeks to increase the platelet count to 50 × 109/L in patients with ITP. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.